Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus (Q44301386)

1 December 2017

Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus (English)

1 reference

1 December 2017

0 references

1 reference

Yoshikazu Hasegawa

1

1 reference

1 December 2017

Akira Suehiro

2

1 reference

1 December 2017

Satoshi Higasa

3

1 reference

1 December 2017

Mitsuyoshi Namba

4

1 reference

1 December 2017

Eizo Kakishita

5

1 reference

1 December 2017

language of work or name

1 reference

1 September 2002

1 reference

1 December 2017

1 reference

1 December 2017

107

1 reference

1 December 2017

319-323

1 reference

1 December 2017

6

1 reference

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Nonenzymatic glycosylation, the Maillard reaction and the aging process

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Increased serum levels of advanced glycation end-products and diabetic complications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Effect of Advanced Glycation End Product–Modified Albumin on Tissue Factor Expression by Monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Increased aggregation of human platelets produced by advanced glycation end products in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Platelet function in diabetes mellitus in relationship to complications, glycosylated haemoglobin and serum lipoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Platelet and plasma vasoactive amines in type 1 (insulin-dependent) diabetes mellitus with and without vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

Enhancement by cyclosporine A and tacrolimus of serotonin-induced formation of small platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2802%2900348-1

7 January 2021

10.1016/S0049-3848(02)00348-1

Identifiers

DOI

1 reference

1 December 2017

1 reference